NeuroSearch is a biopharmaceutical company that develops novel drugs for unmet medicinal needs within diseases of the central nervous system. The company has a broad product development pipeline consisting of products in varying stages of preclinical and clinical investigation, for the treatment of depression, Parkinson’s disease, anxiety disorders, Alzheimer’s disease, cocaine addiction and pain. The lead product is NS2330. The wholly owned subsidiaries of NeuroSearch group are Azign Bioscience, Poseidon Pharmaceuticals and NeuroScreen.